DUBLIN--(BUSINESS WIRE)--The "Global Companion Diagnostic Tests in Oncology Market (2022-2027) by Product & Service, Technology, End User, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global Companion Diagnostic Tests in Oncology Market is estimated to be USD 4.1 Bn in 2022 and is expected to reach USD 7.62 Bn by 2027, growing at a CAGR of 13.2%
Market Dynamics
Drivers
- Accelerating Demand for Targeted Cancer Treatment & Tailored Drugs
- Rise in Cancer Incidence Across the Globe
- Rise in Approval Rate for Companion Diagnostics
Restraints
- Broken Clinical Diagnostic Testing Landscape
- Constraints Associated with the Clinical Implementation of Companion Diagnostic Tests
Opportunities
- Increase in Adoption of Companion Diagnostics for Precision Medicine
- Collaborations Between Diagnostic and Pharma Entities
Challenges
- Reimbursement Challenges Associated with Companion Diagnostic Tests
Market Segmentations
The Global Companion Diagnostic Tests in Oncology Market is segmented based on Product & Service, Technology, End User, and Geography.
- By Product & Service, the market is classified into Product and Service.
- By Technology, the market is classified into PCR, NGS, IHC and ISH/FISH.
- By End User, the market is classified into Hospitals, Pathology / Diagnostic, and Laboratory.
- By Geography, the market is classified into Americas, Europe, Middle East & Africa, and Asia-Pacific.
Countries Studied
- America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
- Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
- Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
- Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)
Ansoff Analysis
The report presents a detailed Ansoff matrix analysis for the Global Companion Diagnostic Tests in Oncology Market. Ansoff Matrix, also known as the Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
The analyst analyses the Global Companion Diagnostic Tests in Oncology Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.
Key Topics Covered:
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Dynamics
5 Market Analysis
6 Global Companion Diagnostic Tests in Oncology Market, By Product & Service
7 Global Companion Diagnostic Tests in Oncology Market, By Technology
8 Global Companion Diagnostic Tests in Oncology Market, By End User
9 Americas' Companion Diagnostic Tests in Oncology Market
10 Europe's Companion Diagnostic Tests in Oncology Market
11 Middle East and Africa's Companion Diagnostic Tests in Oncology Market
12 APAC's Companion Diagnostic Tests in Oncology Market
13 Competitive Landscape
14 Company Profiles
15 Appendix
Companies Mentioned
- Abbott Laboratories
- Abnova Corp.
- Agilent Technologies, Inc.
- Almac Group
- Asuragen, Inc.
- Biogenex Laboratories, Inc.
- Creative Biolabs, Inc.
- Danaher Corp.
- F. Hoffmann-La Roche Ag
- Icon, PLC
- Illumina, Inc.
- Invivoscribe, Inc.
- Meso Scale Diagnostics, LLC.
- Myriad Genetics, Inc.
- Q Solutions
- Qiagen
- Saga Diagnostics
- Sysmex Corp.
- Thermo Fisher Scientific, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/t8p3le
